Taiwania Capital — 2022 Investments
5 investments dated 2022 · listed companies and verified rows first · show all
AESOP develops clinical decision intelligence, a class of medical AI systems that reconstruct and analyze clinical decision-making across diagnosis, treatment, medication management, and medical coding to support physicians and improve patient safety.
AI & Machine LearningDigital HealthHealthtechMarketplacesSaaSTaipei, US
Jeremiah Scholl(Co-founder)inJim LonginYu-Chuan Li(Founder)An-Jim Long(Co-founder)
Co-investors500 GlobalColopl NextGeneral CatalystKleiner Perkins
.png)
Canner builds a data management platform with a universal semantic layer and centralized data catalog, offering connectors for data ingestion, integration, and visualization across multiple data sources.
Data & InfrastructureEnterprise SoftwareSaaS
Co-investorsSparkLabs Taipei
Massachusetts-based developer of millimeter-wave 5G radio access network equipment and software for operators and enterprises.
Waltham, US
Vedat Eyuboglu(Executive Officer, Director)inAmit Jain(Executive Officer, Director)
BoardSanto Politi(Director)in
Co-investorsBold Capital PartnersDC Investment PartnersLockheed Martin VenturesSpark CapitalTDK Ventures
.jpeg){kind=logo}
Windgap Medical designs autoinjector devices for delivering complex drugs and combination products, including systems for reconstituting lyophilized or powdered compounds, sequential delivery of two liquid therapies, high-viscosity medications, and large-volume injections.
BiotechHardwareMedical DevicesWatertown, US
Brent Buchine(Director)inMax Meehan(Executive Officer)inAaron Mann(Executive Officer, Director)inJason Durkin(Executive Officer)inJohn Cadigan(Executive Officer)inAnthony Watson(Executive Officer)in
Co-investorsBantam GroupBoston Harbor AngelsColle Capital PartnersLaunchpad Venture GroupCobro Ventures
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.